AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs.

(Reuters) -AstraZeneca CEO Pascal Soriot is considering moving the company's stock market listing to the U.S., the Times ...

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

What Happened: Its recent definitive agreement to acquire U.K.-based Oxford Ionics for $1.075 billion will “meaningfully accelerate IonQ’s technology roadmap,” said Needham.

In a shock move, AstraZeneca has ditched a plan to invest £450 million ($558 million) in a new vaccine manufacturing plant in the UK, after the government reduced the offer on the table to ...

Khan revealed plans to transform Oxford Street into a pedestrian zone, following support from the public and businesses. "It's clear that the vast majority of Londoners and major businesses back ...

MEDICS have raised concerns over a drug taken by millions to prevent heart attacks and strokes, claiming key safety data was “misreported” by its manufacturer AstraZeneca. Anti-clotting… ...

Comments Oxford city centre is plagued by congestion, the council said (Picture: SWNS) Drivers in Oxford are bracing themselves for a London-style congestion charge zone if plans go ahead.

Review the current valuation for AstraZeneca PLC ADR (AZN:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.